Mountain Valley MD Holdings Inc C.MVMD

From Imminent in March 2021 to first quarter 2023 or beyond

[quietobserver]

1. ONCOLOGY The analysis of proliferation data is being conducted and anticipated to be completed in June 2022. The Company’s broader oncology strategy and future planning will be scheduled in Q3 after the preliminary research and related evaluations are completed. Future planning in Q3
   
   COLD CHAIN MVMD is initiating first phase studies for characterization of targeted antigen and vaccines the week of June 6, 2022 and has completed planning for second phase studies for upcoming temperature and storage testing.--more testing/delays
   
   HUSBANDRY ANIMALS The results of some of the stability testing have now been received and have indicated that the base formula requires optimization and further stability testing in order to allow for the scaling of batch sizes for production and ensuring Soluvec™ 1% product applications have a predictable shelf life. This work is expected to proceed through to the first quarter of 2023.
   It is currently anticipated that Soluvec™ 1% will be ready for retail product introduction by the licensee in the first quarter of 2023, however this may be a longer or shorter period depending on various factors such as the results of the additional stability testing and the related timing of regulatory review and approval.
   
   ACQUACULTURE The Company is working with the Ministry to finalize key protocols in these different species and is completing the trial planning protocol and aims to commence the trials in the third quarter of 2022.
   MVMD is coordinating the research framework with an acclaimed international university to conduct a collaborative study of Soluvec™1% coated fish feed to study its health benefits in targeted aquatic species. It is anticipated the related studies will commence in the in the fourth quarter of 2022.
    
2. [2:05 PM]

   DOSE SPARING ADJUVANT
   The Company continues its work with its key advisors at Tulane University to explore if changes in the adjuvant development and administration may support a positive research outcome across a broad spectrum of vaccines. MVMD anticipates exploratory progress over the third quarter of 2022,
   
   INSULIN The Company’s formulation experiments are planned to be initiated by end of June 2022. • The Company expects to have further information on formulation developments and to complete testing of formulations in a Type 1 diabetes model in the second half of 2022.
   
   TUBERCULOSIS Testing of different concentrations of the base formula to be initiated by end of June 2022 prior to commencing pre-clinical studies with its Selactosol™ 1.5% solution which is anticipated in the latter half of 2022.
   
   NUTRACEUTICALS The dissolution work was successfully demonstrated in May of 2022 and the Company is working with it production partner on final production scale requirements and anticipates it will be capable of full commercial scale GMP product manufacturing that embodies the MVMD’s proprietary Quicksome™ technology in the third quarter of 2022.
   
   Securing the lead manufacturer and finalizing the scaled GMP production environment aligns with MVMD’s anticipated increased business development efforts in the latter half of 2022 to secure additional nutraceutical licensing partnerships.